CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3

被引:47
作者
Hulgan, T
Raffanti, S
Kheshti, A
Blackwell, RB
Rebeiro, PF
Barkanic, G
Ritz, B
Sterling, TR
机构
[1] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37203 USA
[2] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37203 USA
[3] Comprehens Care Ctr, Nashville, TN USA
关键词
D O I
10.1086/432955
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The optimal timing of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV)-infected patients with >= 200 absolute CD4 lymphocytes/mm(3) is unknown. CD4 lymphocyte percentage could add prognostic information. Methods. Persons who initiated HAART between 1 January 1998 and 1 January 2003, received >= 30 days of therapy, and had baseline CD4 lymphocyte data available were included in the study. The log-rank test for time to event and Cox proportional hazards models were used to determine predictors of a new acquired immunodeficiency syndrome - defining illness or death. Results. A total of 788 patients met the inclusion criteria. At baseline, subjects had a median of 225 CD4 lymphocytes/mm(3) and 17% CD4 lymphocytes. Subjects with >= 17% CD4 lymphocytes had earlier disease progression, compared with subjects with >= 17%, both in the entire cohort (P <.001) and of those subjects with > 350 absolute CD4 lymphocytes/mm(3) at baseline (P=.03). CD4 lymphocyte percentage < 17% was the strongest predictor of disease progression among subjects in this latter group (hazard ratio, 3.57; P = .045). Conclusions. In this cohort, CD4 lymphocyte percentage predicted disease progression in HIV-infected subjects who initiated therapy with 1350 CD4 lymphocytes/mm(3). This information may help identify persons who will derive the greatest benefit from initiation of HAART.
引用
收藏
页码:950 / 957
页数:8
相关论文
共 25 条
[1]  
[Anonymous], 1992, MMWR-MORBID MORTAL W, V41, P1
[2]   Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients [J].
Barbaro, G ;
Klatt, EC .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (18) :1475-1481
[3]   CD4-PERCENT IS THE BEST PREDICTOR OF DEVELOPMENT OF AIDS IN A COHORT OF HIV-INFECTED HOMOSEXUAL MEN [J].
BURCHAM, J ;
MARMOR, M ;
DUBIN, N ;
TINDALL, B ;
COOPER, DA ;
BERRY, G ;
PENNY, R .
AIDS, 1991, 5 (04) :365-372
[4]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[5]   HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management [J].
Carr, A .
AIDS, 2003, 17 :S141-S148
[6]  
*DHHS, 2003, GUID US ANT AG HIV 1, V2003
[7]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[8]   Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection [J].
Gebo, KA ;
Gallant, JE ;
Keruly, JC ;
Moore, RD .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (05) :1028-1033
[9]   Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy [J].
Gulick, RM ;
Mellors, JW ;
Havlir, D ;
Eron, JJ ;
Gonzalez, C ;
McMahon, D ;
Richman, DD ;
Valentine, FT ;
Jonas, L ;
Meibohm, A ;
Emini, EA ;
Chodakewitz, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :734-739
[10]   Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection [J].
Gulick, RM ;
Ribaudo, HJ ;
Shikuma, CM ;
Lustgarten, S ;
Squires, KE ;
Meyer, WA ;
Acosta, EP ;
Schackman, BR ;
Pilcher, CD ;
Murphy, RL ;
Maher, WE ;
Witt, MD ;
Reichman, RC ;
Snyder, S ;
Klingman, KL ;
Kuritzkes, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (18) :1850-1861